2022
Endogenous Retroviruses Provide Protection Against Vaginal HSV-2 Disease
Jayewickreme R, Mao T, Philbrick W, Kong Y, Treger RS, Lu P, Rakib T, Dong H, Dang-Lawson M, Guild WA, Lau TJ, Iwasaki A, Tokuyama M. Endogenous Retroviruses Provide Protection Against Vaginal HSV-2 Disease. Frontiers In Immunology 2022, 12: 758721. PMID: 35058919, PMCID: PMC8764156, DOI: 10.3389/fimmu.2021.758721.Peer-Reviewed Original ResearchConceptsHSV-2 infectionHSV-2 diseaseHerpes simplex virus type 2 infectionSimplex virus type 2 infectionEnhanced type I interferonIntravaginal HSV-2 infectionVaginal HSV-2 infectionVirus type 2 infectionEndogenous retrovirusesReceptor-deficient miceType 2 infectionHigh systemic levelsWildtype C57BL/6 miceType I interferonTLR7-/- miceC57BL/6 miceInfectious endogenous retrovirusDeficient miceIntravaginal applicationAntiviral immunityI interferonVaginal tissueDetrimental functionsTLR7Mice
2021
Endogenous retroviruses mediate IFN-independent protection against vaginal HSV-2 infection
Tokuyama M, Jayewickreme R, Mao T, Philbrick W, Kong Y, Dong H, Treger R, Rakib T, Iwasaki A. Endogenous retroviruses mediate IFN-independent protection against vaginal HSV-2 infection. The Journal Of Immunology 2021, 206: 20.39-20.39. DOI: 10.4049/jimmunol.206.supp.20.39.Peer-Reviewed Original ResearchHSV-2 infectionVaginal HSV-2 infectionTight junction proteinsB6 miceVaginal epitheliumHerpes simplex virus type 2 infectionSimplex virus type 2 infectionEnhanced type I interferonIntravaginal HSV-2 infectionVirus type 2 infectionToll-like receptor 7Epithelial tight junction proteinsEndogenous retrovirusesReceptor-deficient miceJunction proteinsType 2 infectionHigh systemic levelsWildtype C57BL/6 miceType I interferonDisease courseC57BL/6 miceInfectious endogenous retrovirusReceptor 7Disease burdenHSV-2
2019
Successful application of prime and pull strategy for a therapeutic HSV vaccine
Bernstein DI, Cardin RD, Bravo FJ, Awasthi S, Lu P, Pullum DA, Dixon DA, Iwasaki A, Friedman HM. Successful application of prime and pull strategy for a therapeutic HSV vaccine. Npj Vaccines 2019, 4: 33. PMID: 31396405, PMCID: PMC6671986, DOI: 10.1038/s41541-019-0129-1.Peer-Reviewed Original ResearchHerpes simplex virus type 2PBS control groupRecurrent sheddingControl groupVaginal HSV-2 infectionSimplex virus type 2Herpes simplex virus vaccineRecurrent HSV diseaseTherapeutic HSV vaccinesHSV-2 infectionCombinations of vaccinesGuinea pig modelVirus type 2Imiquimod groupHSV diseaseHSV vaccineRecurrent diseaseRecurrent lesionsRecurrent HSVVaccinated groupGlycoprotein vaccineTrivalent vaccineImmune cellsVirus vaccineGenital tract